Investigation of the effect of ethylmethylhydroxypyridine succinate on the effectiveness of non-steroidal anti-inflammatory drugs for visceral and somatic pain in mice and rats

Close metadata

OBJECTIVE

To study the effect of ethylmethylhydroxypyridine succinate (EMHPS) on the analgesic effect of the non-selective cyclooxygenase (COX) inhibitor diclofenac sodium and the selective COX-2 inhibitor etoricoxib in models of acute visceral and somatic pain and to evaluate the possibility of using EMHPS in combination with COX inhibitors to reduce their doses while maintaining analgesic efficiency.

MATERIAL AND METHODS

We studied the effect of EMHPS with a single oral administration on the analgesic effects of non-steroidal anti-inflammatory drugs (NSAIDs): the non-selective COX inhibitor diclofenac sodium and the selective COX-2 inhibitor etoricoxib — on models of acute visceral (vinegar writhing test) and somatic pain (formalin test and mechanical hyperalgesia during inflammation) in an experiment on mice and rats.

RESULTS

In a model of acute visceral pain in mice, EMGPS (25—100 mg/kg) does not have a significant effect on its severity, but enhances the analgesic effect of diclofenac sodium (0.5 mg/kg) and etoricoxib (1 mg/kg). In the formalin test in rats, which simulates pain during surgical incisions (trauma), EMGPS (25 mg/kg) increases the severity of the analgesic effect of COX inhibitors (1 mg/kg), primarily by reducing pain in the acute phase caused by the effect of formalin on afferent neurons. In a model of mechanical hyperalgesia in rats caused by exudative inflammation after injection of a carrageenan solution into the paw, EMHPS enhances the effect of diclofenac to a greater extent than etoricoxib.

CONCLUSION

The data obtained indicate the feasibility of a clinical study of the use of EMGPS in combination with NSAIDs for visceral and somatic pain in order to assess its ability to increase the therapeutic effect of NSAIDs.

Keywords:

ethylmethylhydroxypyridine succinate

non-steroidal anti-inflammatory drugs

visceral pain

somatic pain

mice

rats

Authors:

Ivanova E.A.

Zakusov Institute of Pharmacology

SPIN RSCI: 5005-0337
Scopus AuthorID: 57193642138
ResearcherID: E-2973-2017
ORCID: 0000-0003-4961-2051

Vasilchuk A.G.

Zakusov Institute of Pharmacology

ORCID: 0000-0002-9079-1322

Matyushkin A.I.

Zakusov Institute of Pharmacology

ORCID: 0000-0001-7640-0551

Voronina T.A.

Zakusov Institute of Pharmacology

SPIN RSCI: 5766-3452
Scopus AuthorID: 7103337584
ResearcherID: A-5990-2017
ORCID: 0000-0001-7065-469X

Received:

03.10.2023

Accepted:

04.10.2023

List of references:

Karateev AE, Nasonov EL, Ivashkin VT, et al. Clinical guidelines. Nauchno-Prakticheskaja Revmatologija. 2018;56(1):1-29. (In Russ.). https://doi.org/10.14412/1995-4484-2018-1-29
Ross A, Hauser MD. Wonder why? The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-inflammatory Drugs. J Prolother. 2010;2(1):305-322.
O’Neil CK, Hanlon JT, Marcum ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: Focus on non-opioid and opioid analgesics. Am J Geriat Pharmacother. 2012;10(6):331-342. https://doi.org/10.1016/j.amjopharm.2012.09.004
Eling TE, Curtis JF. Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther. 1992;53(2):261-273. https://doi.org/10.1016/0163-7258(92)90012-o
Wang ZQ, Porreca F, Cuzzocrea S, et al. A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther. 2004;309(3):869-878. https://doi.org/10.1124/jpet.103.064154
Khattab MM. TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite- and superoxide anion-enhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. Eur J Pharmacol. 2006;548(1-3):167-173. https://doi.org/10.1016/j.ejphar.2006.08.007
Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidant vulnerable: A molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharm Sci. 1998;19(8):328-334. https://doi.org/10.1016/s0165-6147(98)01230-9
Maher P, Schubert D. Signaling by reactive oxygen species in the nervous system. Cell Mol Life Sci. 2000;57(8):1287-1305. https://doi.org/10.1007/pl00000766
Foran E, Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxidants & Redox Signaling. 2009;11(7):1587-1602. https://doi.org/10.1089/ars.2009.2444
Sandoval-Acuña C, Lopez-Alarcón C, Aliaga ME, Speisky H. Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action. Chem Biol Interact. 2012;199(1):18-28. https://doi.org/10.1016/j.cbi.2012.05.006
Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-2913. https://doi.org/10.1161/circulationaha.106.616219
Nikol’skaia IN, Khromova OM, Irkhina IS, et al. Comparative evaluation of clinical efficacy and safety of mexidol in patients with acute coronary syndrome in addition to standart regimen of treatment. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2013;6(3):37-42. (In Russ.).
Voronina TA. Mexidol: main neuropsychotropic effects and mechanisms of action. Farmateka. 2009;6(180):35-38. (In Russ.).
Dumaev KM, Voronina TA, Smirnov LD. Antioxidants in the prevention and therapy of Central nervous system pathologies. M.: Publishing House of the Institute of Biomedical Chemistry; 1995. (In Russ.).
Burlakova EB, Kairane ChB, Molochkina EM, Khokhlov AP. Membrane-modulating effects of 3-hydroxypyridine derivatives. Voprosy Meditsinskoi Khimii. 1984;30(1):66-72. (In Russ.).
Shchulkin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39. (In Russ.).
Lukyanova LD. Current issues of adaptation to hypoxia. signal mechanisms and their role in system regulation. Patologicheskaya Fiziologiya i Ehksperimental’naya Terapiya. 2011;(1):3-19. (In Russ.).
Lukyanova LD. Signal’nye Mekhanizmy Gipoksii. M.: RAS; 2019. (In Russ.).
Voronina TA, Guzevatykh LS. Metodicheskie rekomendatsii po izucheniyu anal’geticheskoi aktivnosti lekarstvennykh sredstv. M.: Grif and K; 2012. (In Russ.).
McNamara CR, Mandel-Brehm J, Bautista DM, et al. TRPA1 mediates formalin-induced pain. Proc Nat Acad Sci. 2007;104(33):13525-13530. https://doi.org/10.1073/pnas.0705924104
Fisher M, Carli G, Raboisson P, Reeh P. The interphase of the formalin test. Pain. 2014;155(3):511-521. https://doi.org/10.1016/j.pain.2013.11.015
Gouin O, L’Herondelle K, Lebonvallet N, et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization. Protein & Cell. 2017;8(9):644-661. https://doi.org/10.1007/s13238-017-0395-5
Kanai Y, Hara T, Imai A. Participation of the spinal TRPV1 receptors in formalin-evoked pain transduction: a study using a selective TRPV1 antagonist, iodoresiniferatoxin. J Pharm Pharmacol. 2006;58(4):489-493. https://doi.org/10.1211/jpp.58.4.0008
Nozadze I, Tsiklauri N, Gurtskaia G, Tsagareli MG. NSAIDs attenuate hyperalgesia induced by TRP channel activation. Data in Brief. 2016;6:668-673. https://doi.org/10.1016/j.dib.2015.12.055
Ivanova EA, Matyushkin AI, Vasilchuk AG, Voronina TA. Ability of mexidol to enhance antiexudative effect of diclofenac sodium and etoricoxib in rats and mice with carrageenan-induced edema. Moscow University Biological Sciences Bulletin. 2021;76(2):61-66. (In Russ.). https://doi.org/10.3103/S0096392521020024
Ivanova EA, Vasil’chuk AG, Matyushkin AI, Voronina TA. Enhancement of the anti-inflammatory and analgesic effect of diclofenac sodium in combination with mexidol. Ehksperimental’naya i Klinicheskaya Farmakologiya. 2020;83(7):22-26. (In Russ.). https://doi.org/10.30906/0869-2092-2020-83-7-22-26
Ivanova EA, Vasil’chuk AG, Matyushkin AI, Voronina TA. Effect of the combination of mexidol and diclofenac sodium on exudative inflammation in rats after ten-day preventive oral administration. Farmakokinetika i Farmakodinamika. 2022;(1):14-19. (In Russ.). https://doi.org/10.37489/2587-7836-2022-1-14-19
Ivanova EA, Dmitrieva SA, Zolotov NN, Voronina TA. The effect of diclofenac sodium and its combinations with mexidol on Fe2+-induced chemiluminescence. Pharmaceutical Chemistry Journal. 2023;57(5):9-13. (In Russ.). https://doi.org/10.30906/0023-1134-2023-57-5-9-13
Shatrova VP, Meskhi KT. The use of antioxidants in the complex treatment of vertebrogenic neurovascular syndromes. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(7):79-81. (In Russ.).
Likhacheva EB. Mexidol in the conservative treatment of lumbosacral radiculopathy. Farmateka. 2012;6(239):83-87. (In Russ.).
Likhacheva EB, Sholomov II. Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2006;106(10):52-57. (In Russ.).
Khuzhakhmetova DH. The use of Mexidol in a standardized regimen for the treatment of osteochondrosis of the spine. Byulleten’ Ehksperimental’noi Biologii i Meditsiny. 2012;1:219-225. (In Russ.).
Sinchenko OG. The use of antihypoxant and neurometabolic properties of Mexidol in the treatment of vertebrogenic radiculoishemic syndrome. Byulleten’ Ehksperimental’noi Biologii i Meditsiny. 2012;1:60-62. (In Russ.).
Andreev VV. Complex treatment of spondylo genic radiculo-ischemia with the use of Mexidol. Byulleten’ Ehksperimental’noi Biologii i meditsiny. 2012;S1:63-68. (In Russ.).

Close metadata